I was recruited to Cedars-Sinai to direct the Inflammatory Bowel Diseases Drug Discovery and Development (IBD3) unit for the Inflammatory Bowel and Immunobiology Research Institute. IBD3 is a unique concept by design, in which an industry-caliber target discovery and development unit is integrated with an academic research program to accelerate the pace at which scientific findings are brought to bear on patient care."
The Bilsborough Laboratory's Inflammatory Bowel Diseases Drug Discovery and Development unit is composed of research scientists and clinicians with experience in both the biopharmaceutical industry and clinical research.
Meet Our Team
Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Bilsborough Laboratory, whose dedicated efforts lead to groundbreaking discoveries.
Bilsborough J, Fiorino MF, Henkle BW.
Expert Opin Drug Discov. 2021 May;16(5):567-577.
Potdar AA, Dube S, Naito T, Li K, Botwin G, Haritunians T, Li D, Casero D, Yang S, Bilsborough J, et al.
Gastroenterology. 2021 Feb;160(3):809-822.
Potdar AA, Li D, Haritunians T, VanDussen KL, Fiorino MF, Liu TC, Stappenbeck TS, Fleshner P, Targan SR, McGovern DPB, Bilsborough J.
J Crohns Colitis. 2019 Aug 14;13(8):1055-1066.
Gonsky R, Fleshner P, Deem RL, Biener-Ramanujan E, Li D, Potdar AA, Bilsborough J, Yang S, McGovern DPB, Targan SR.
Gastroenterology. 2017 Jul;153(1):219-232.